Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

Part of paid clinical trials in San Francisco, California.

Sponsor
University of Miami
Study ID
NCT06663722
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Axatilimab — BIOLOGICAL
    Axatilimab will be administered intravenously (IV) at a dose of 0.3 mg/kg, beginning as a pre-phase dose two weeks prior to initiation of Extracorporeal Photopheresis (ECP) therapy. Thereafter, Axatilimab will be administered with a frequency of one treatment session bi-weekly during each treatment cycle.
  • Extracorporeal Photopheresis — PROCEDURE
    Mandatory ECP therapy will be administered at a frequency of two treatment sessions per week during Cycles 1 through 3, two treatment bi-weekly during Cycles 4 through 6, and two treatments during week 1 of Cycle 7. Optional ECP therapy will be administered at a frequency of two treatment sessions during weeks 2 and 4 of Cycles 4 through 6, when mandatory ECP is not administered. Optional ECP therapy will also be administered as two treatment sessions during week 3 of Cycle 7. After Cycle 7, participants may receive ECP therapy only at the Investigator's discretion for a maximum Treatment Period of 12 months.

Study Details

The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).

Key Dates

First listed
Oct 29, 2024
Start date
May 5, 2025
Status verified
Jun 2026
Primary completion
May 5, 2030
Completion
May 5, 2030

Study Design

Enrollment
49 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Axatilimab in combination with ECP Group
    Participants in this group will receive Axatilimab in combination with extracorporeal photopheresis (ECP) therapy for up to seven (7) four-week cycles. Total participation duration is about 15 months.

Primary Outcome Measure

Best Overall Response Rate (ORR) [ Time Frame: Up to 24 weeks ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Jerry Lee, MD, MS
[email protected]
Jerry Lee, MD, MS (PRINCIPAL_INVESTIGATOR)
University of MiamiMiamiFlorida33136
Trent P Wang, DO
[email protected]
305-243-6444
Trent P Weng, DO (PRINCIPAL_INVESTIGATOR)
Ann & Robert H. Lurie Children's Hospital of ChicagoChicagoIllinois60611
Jennifer Schneiderman, MD, MS
[email protected]
Jennifer Schneiderman, MD,MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CAUniversity of Miami· Miami, FLAnn & Robert H. Lurie Children's Hospital of Chicago· Chicago, IL

Related Studies